HK1129115A1 - Renin inhibitors - Google Patents
Renin inhibitorsInfo
- Publication number
- HK1129115A1 HK1129115A1 HK09109173.1A HK09109173A HK1129115A1 HK 1129115 A1 HK1129115 A1 HK 1129115A1 HK 09109173 A HK09109173 A HK 09109173A HK 1129115 A1 HK1129115 A1 HK 1129115A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- renin inhibitors
- renin
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Ophthalmology & Optometry (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Hydrogenated Pyridines (AREA)
- Pyrane Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US84529106P | 2006-09-18 | 2006-09-18 | |
PCT/US2007/020164 WO2008036247A1 (en) | 2006-09-18 | 2007-09-18 | Renin inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1129115A1 true HK1129115A1 (en) | 2009-11-20 |
Family
ID=38786973
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK09109173.1A HK1129115A1 (en) | 2006-09-18 | 2009-10-05 | Renin inhibitors |
Country Status (23)
Country | Link |
---|---|
US (2) | US8198453B2 (sr) |
EP (2) | EP2074108B3 (sr) |
JP (1) | JP5331695B2 (sr) |
KR (1) | KR20090064582A (sr) |
CN (1) | CN101528723B (sr) |
AR (1) | AR062797A1 (sr) |
AU (1) | AU2007297729C1 (sr) |
BR (1) | BRPI0718460A2 (sr) |
CA (1) | CA2663263A1 (sr) |
CL (1) | CL2007002689A1 (sr) |
DK (1) | DK2074108T3 (sr) |
ES (1) | ES2400009T7 (sr) |
HK (1) | HK1129115A1 (sr) |
HR (1) | HRP20130144T4 (sr) |
MX (1) | MX2009002740A (sr) |
NZ (1) | NZ575803A (sr) |
PE (1) | PE20080843A1 (sr) |
PL (1) | PL2074108T6 (sr) |
PT (1) | PT2074108E (sr) |
RS (1) | RS52679B (sr) |
SI (1) | SI2074108T1 (sr) |
TW (1) | TWI403510B (sr) |
WO (1) | WO2008036247A1 (sr) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2440993C2 (ru) | 2004-10-07 | 2012-01-27 | Вайти Фармасьютикл, Инк. | Диаминоалкановые ингибиторы аспарагиновой протеазы |
TWI411607B (zh) * | 2005-11-14 | 2013-10-11 | Vitae Pharmaceuticals Inc | 天門冬胺酸蛋白酶抑制劑 |
WO2008036216A1 (en) * | 2006-09-18 | 2008-03-27 | Vitae Pharmaceuticals, Inc. | Piperidine derivatives as renin inhibitors |
CL2007002689A1 (es) | 2006-09-18 | 2008-04-18 | Vitae Pharmaceuticals Inc | Compuestos derivados de piperidin-1-carboxamida, inhibidores de la renina; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hipertension, insuficiencia cardiaca, fibrosis cardiaca, entre otras. |
EP2170815A2 (en) * | 2007-06-20 | 2010-04-07 | Vitae Pharmaceuticals, Inc. | Renin inhibitors |
WO2009096996A1 (en) * | 2007-06-20 | 2009-08-06 | Smithkline Beecham Corporation | Renin inhibitors |
US20110160300A1 (en) * | 2008-06-20 | 2011-06-30 | Marlys Hammond | Renin Inhibitors and Methods of Use Thereof |
US20100010228A1 (en) * | 2008-06-26 | 2010-01-14 | Vitae Pharmaceuticals, Inc. | Process for the asymmetric reduction of 3-benzoylpiperidines |
MX2010014557A (es) * | 2008-06-26 | 2011-02-15 | Vitae Pharmaceuticals Inc | Sales de 2-((r)-(3-clorofenil)((r)-1-((s)-2-(metilamino)-3-((r)-te trahidro-2h-piran-3-il)propilcarbamoil)piperidin-3-il)metoxi)etil carbamato de metilo. |
AU2013248242B2 (en) * | 2009-03-18 | 2016-08-18 | Incarda Therapeutics, Inc | Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration |
EP3552603A1 (en) | 2009-03-18 | 2019-10-16 | Incarda Therapeutics, Inc. | Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration |
AU2016256776B2 (en) * | 2009-03-18 | 2018-04-12 | Incarda Therapeutics, Inc. | Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration |
AR077692A1 (es) | 2009-08-06 | 2011-09-14 | Vitae Pharmaceuticals Inc | Sales de 2-((r)-(3-clorofenil) ((r)-1-((s) -2-(metilamino)-3-((r)-tetrahidro-2h-piran-3-il) propilcarbamoil) piperidin -3-il) metoxi) etilcarbamato de metilo |
EP3411030A4 (en) | 2016-02-01 | 2019-09-04 | InCarda Therapeutics, Inc. | COMBINING ELECTRONIC SURVEILLANCE WITH INHALATION PHARMACOLOGICAL THERAPY FOR MANAGING CARDIAC ARRHYTHMIAS WITH ATRIAL FIBRILLATION |
EP3621616A4 (en) | 2017-05-10 | 2021-01-13 | InCarda Therapeutics, Inc. | UNIT DOSE, AEROSOLS, KITS AND METHODS FOR TREATMENT OF HEART DISEASE BY PULMONAL ADMINISTRATION |
WO2019183470A2 (en) | 2018-03-22 | 2019-09-26 | Incarda Therapeutics, Inc. | A novel method to slow ventricular rate |
US11007185B2 (en) | 2019-08-01 | 2021-05-18 | Incarda Therapeutics, Inc. | Antiarrhythmic formulation |
Family Cites Families (85)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3071618A (en) | 1956-02-02 | 1963-01-01 | Pfizer & Co C | Diquaternary ammonium salts of n, n, n', n'-tetra substituted alkylene diamines |
GB1351761A (en) | 1971-02-04 | 1974-05-01 | Wilkinson Sword Ltd | Substituted p-menthane carboxamides and compositions containing them |
US4136163A (en) | 1971-02-04 | 1979-01-23 | Wilkinson Sword Limited | P-menthane carboxamides having a physiological cooling effect |
JPS5115098A (ja) | 1974-07-26 | 1976-02-06 | Asahi Chemical Ind | Akurirukeiseniseihinno shorihoho |
US4826689A (en) | 1984-05-21 | 1989-05-02 | University Of Rochester | Method for making uniformly sized particles from water-insoluble organic compounds |
US4594343A (en) | 1984-10-19 | 1986-06-10 | Shanklin Jr James R | 1-[(aminoalkyl and aminoalkylamino)carbonyl and thiocarbonyl]-α,α-diarylpyrrolidine, piperidine and homopiperidineacetamides and acetonitriles |
GB8810067D0 (en) | 1988-04-28 | 1988-06-02 | Ucb Sa | Substituted 1-(1h-imidazol-4-yl)alkyl-benzamides |
FR2634376B1 (fr) | 1988-07-21 | 1992-04-17 | Farmalyoc | Nouvelle forme unitaire, solide et poreuse comprenant des microparticules et/ou des nanoparticules, ainsi que sa preparation |
US4908372A (en) | 1988-10-13 | 1990-03-13 | Merrell Dow Pharmaceuticals Inc. | Antihistaminic piperidinyl benzimidazoles |
IT1227626B (it) | 1988-11-28 | 1991-04-23 | Vectorpharma Int | Farmaci supportati aventi velocita' di dissoluzione aumentata e procedimento per la loro preparazione |
US5539122A (en) | 1989-05-23 | 1996-07-23 | Abbott Laboratories | Retroviral protease inhibiting compounds |
US5821232A (en) | 1990-05-11 | 1998-10-13 | Pfizer Inc. | Synergistic therapeutic compositions and methods |
DK0527879T3 (da) | 1990-05-11 | 1997-07-14 | Pfizer | Synergistiske terapeutiske præparater og fremgangsmåder. |
DE4018070A1 (de) | 1990-06-06 | 1991-12-12 | Bayer Ag | Morpholinoharnstoff-derivate |
IT1243390B (it) | 1990-11-22 | 1994-06-10 | Vectorpharma Int | Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione. |
HUT64320A (en) | 1990-12-14 | 1993-12-28 | Merrell Dow Pharma | Process for production antiallergic imidazole derivatives and pharmaceutical preparations containing these compounds |
US5552160A (en) | 1991-01-25 | 1996-09-03 | Nanosystems L.L.C. | Surface modified NSAID nanoparticles |
US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
PT626968E (pt) | 1992-02-13 | 2002-03-28 | Merrell Pharma Inc | Derivados de piperidinilo tiaciclicos |
DK0644755T3 (da) | 1992-06-10 | 1997-09-22 | Nanosystems Llc | Overflademodificerede NSAID-nanopartikler |
NZ248813A (en) | 1992-11-25 | 1995-06-27 | Eastman Kodak Co | Polymeric grinding media used in grinding pharmaceutical substances |
US5298262A (en) | 1992-12-04 | 1994-03-29 | Sterling Winthrop Inc. | Use of ionic cloud point modifiers to prevent particle aggregation during sterilization |
US5346702A (en) | 1992-12-04 | 1994-09-13 | Sterling Winthrop Inc. | Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization |
US5302401A (en) | 1992-12-09 | 1994-04-12 | Sterling Winthrop Inc. | Method to reduce particle size growth during lyophilization |
US5340564A (en) | 1992-12-10 | 1994-08-23 | Sterling Winthrop Inc. | Formulations comprising olin 10-G to prevent particle aggregation and increase stability |
US5336507A (en) | 1992-12-11 | 1994-08-09 | Sterling Winthrop Inc. | Use of charged phospholipids to reduce nanoparticle aggregation |
US5429824A (en) | 1992-12-15 | 1995-07-04 | Eastman Kodak Company | Use of tyloxapole as a nanoparticle stabilizer and dispersant |
US5352459A (en) | 1992-12-16 | 1994-10-04 | Sterling Winthrop Inc. | Use of purified surface modifiers to prevent particle aggregation during sterilization |
US5587143A (en) | 1994-06-28 | 1996-12-24 | Nanosystems L.L.C. | Butylene oxide-ethylene oxide block copolymer surfactants as stabilizer coatings for nanoparticle compositions |
ATE187160T1 (de) | 1994-07-29 | 1999-12-15 | Abbott Lab | Verfahren zur herstellung eines substituierten 2,5-diamino-3-hydroxy hexanes |
US5767144A (en) | 1994-08-19 | 1998-06-16 | Abbott Laboratories | Endothelin antagonists |
US6946481B1 (en) | 1994-08-19 | 2005-09-20 | Abbott Laboratories | Endothelin antagonists |
US6162927A (en) | 1994-08-19 | 2000-12-19 | Abbott Laboratories | Endothelin antagonists |
US5585108A (en) | 1994-12-30 | 1996-12-17 | Nanosystems L.L.C. | Formulations of oral gastrointestinal therapeutic agents in combination with pharmaceutically acceptable clays |
US5665331A (en) | 1995-01-10 | 1997-09-09 | Nanosystems L.L.C. | Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers |
US5560932A (en) | 1995-01-10 | 1996-10-01 | Nano Systems L.L.C. | Microprecipitation of nanoparticulate pharmaceutical agents |
US5662883A (en) | 1995-01-10 | 1997-09-02 | Nanosystems L.L.C. | Microprecipitation of micro-nanoparticulate pharmaceutical agents |
US5569448A (en) | 1995-01-24 | 1996-10-29 | Nano Systems L.L.C. | Sulfated nonionic block copolymer surfactants as stabilizer coatings for nanoparticle compositions |
US5560931A (en) | 1995-02-14 | 1996-10-01 | Nawosystems L.L.C. | Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids |
US5571536A (en) | 1995-02-06 | 1996-11-05 | Nano Systems L.L.C. | Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids |
US5503723A (en) | 1995-02-08 | 1996-04-02 | Eastman Kodak Company | Isolation of ultra small particles |
US5518738A (en) | 1995-02-09 | 1996-05-21 | Nanosystem L.L.C. | Nanoparticulate nsaid compositions |
US5622938A (en) | 1995-02-09 | 1997-04-22 | Nano Systems L.L.C. | Sugar base surfactant for nanocrystals |
US5534270A (en) | 1995-02-09 | 1996-07-09 | Nanosystems Llc | Method of preparing stable drug nanoparticles |
US5591456A (en) | 1995-02-10 | 1997-01-07 | Nanosystems L.L.C. | Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer |
US5573783A (en) | 1995-02-13 | 1996-11-12 | Nano Systems L.L.C. | Redispersible nanoparticulate film matrices with protective overcoats |
US5510118A (en) | 1995-02-14 | 1996-04-23 | Nanosystems Llc | Process for preparing therapeutic compositions containing nanoparticles |
US5580579A (en) | 1995-02-15 | 1996-12-03 | Nano Systems L.L.C. | Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers |
US5718919A (en) | 1995-02-24 | 1998-02-17 | Nanosystems L.L.C. | Nanoparticles containing the R(-)enantiomer of ibuprofen |
US5747001A (en) | 1995-02-24 | 1998-05-05 | Nanosystems, L.L.C. | Aerosols containing beclomethazone nanoparticle dispersions |
US5565188A (en) | 1995-02-24 | 1996-10-15 | Nanosystems L.L.C. | Polyalkylene block copolymers as surface modifiers for nanoparticles |
TR199800409T1 (xx) | 1995-09-07 | 1998-05-21 | F.Hoffmann-La Roche Ag | Kalp ve b�brek yetersizli�inin tedavii�in yeni 4-(oksialkoksifenil)-3-oksi-piperidinler |
WO1998035666A1 (en) | 1997-02-13 | 1998-08-20 | Nanosystems Llc | Formulations of nanoparticle naproxen tablets |
CA2291157A1 (en) | 1997-05-29 | 1998-12-03 | Eli Lilly And Company | Process for preparing heterocyclic compounds |
WO1999054321A1 (en) | 1998-04-21 | 1999-10-28 | Aventis Pharma Limited | Substituted diamines and their use as cell adhesion inhibitors |
US6437146B1 (en) | 1998-09-25 | 2002-08-20 | Fujisawa Pharmaceutical Co., Ltd. | Oxazole compounds as prostaglandin e2 agonists or antagonists |
GB9826540D0 (en) * | 1998-12-02 | 1999-01-27 | Darwin Discovery Ltd | Process |
AU2492500A (en) | 1999-01-06 | 2000-07-24 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Aspartic protease inhibitors, compositions, and associated therapeutic methods |
JP2000302757A (ja) | 1999-04-16 | 2000-10-31 | Shiseido Co Ltd | N−置換ピペリジン誘導体 |
SK13632002A3 (sk) | 2000-03-21 | 2003-02-04 | Smithkline Beecham Corporation | C1-6-alkyl-4-amino-azepán-3-ónové zlúčeniny, spôsob ich prípravy, farmaceutický prostriedok s ich obsahom, ich použitie a medziprodukty |
US6900329B2 (en) | 2001-03-21 | 2005-05-31 | Schering Corporation | MCH antagonists and their use in the treatment of obesity |
JP4278511B2 (ja) | 2001-07-11 | 2009-06-17 | イーラン ファーマスーティカルズ、インコーポレイテッド | N−(3−アミノ−2−ヒドロキシ−プロピル)置換アルキルアミド化合物 |
AU2002359376B2 (en) | 2001-11-08 | 2008-01-10 | Elan Pharmaceuticals, Inc. | N, N'-substituted-1,3-diamino-2-hydroxypropane derivatives |
KR100987815B1 (ko) | 2002-04-26 | 2010-10-18 | 길리애드 사이언시즈, 인코포레이티드 | Hiv 프로테아제 억제제 화합물의 포스포네이트유사체의 세포 축적 |
WO2004002483A1 (en) | 2002-06-27 | 2004-01-08 | Actelion Pharmaceuticals Ltd | Substituted 3- and 4- aminomethylpiperidines for use as beta-secretase in the treatment of alzheimer’s disease |
US7557137B2 (en) | 2002-08-05 | 2009-07-07 | Bristol-Myers Squibb Company | Gamma-lactams as beta-secretase inhibitors |
BR0314180A (pt) | 2002-09-10 | 2005-08-09 | Pharmacia & Upjohn Co Llc | Aminoéteres substituìdos para o tratamento da doença de alzheimer |
NZ546887A (en) | 2003-11-03 | 2009-04-30 | Probiodrug Ag | Combinations useful for the treatment of neuronal disorders |
CA2547551A1 (en) * | 2003-12-05 | 2005-06-16 | Actelion Pharmaceuticals Ltd | Diazabicyclononene and tetrahydropyridine derivatives with a new side-chain |
US20070093492A1 (en) | 2004-03-09 | 2007-04-26 | Weir-Torn Jiaang | Pyrrolidine derivatives |
WO2006023844A2 (en) | 2004-08-20 | 2006-03-02 | Entremed, Inc. | Compositions and methods comprising proteinase activated receptor antagonists |
RU2440993C2 (ru) * | 2004-10-07 | 2012-01-27 | Вайти Фармасьютикл, Инк. | Диаминоалкановые ингибиторы аспарагиновой протеазы |
MX2007009004A (es) * | 2005-01-28 | 2007-09-14 | Actelion Pharmaceuticals Ltd | Ciclopropil-(2,3-dimetilbencidamida del acido 7-{4-[2-(2,6-dicloro-4-metilfenoxi) etoxi] fenil}-3,9-diazabiciclo [3.3.31]non-6-en-s-carboxilico como inhbidores de renina para el tratamiento de hipertension. |
JP2008528691A (ja) * | 2005-02-02 | 2008-07-31 | ビテ ファーマシューティカルズ, インコーポレイテッド | レニン阻害剤としての1−アシルアミノ−2−ヒドロキシ−3−アミノ−ω−アリールアルカン |
US7585886B2 (en) | 2005-05-19 | 2009-09-08 | Astellas Pharma Inc. | Pyrrolidine derivative or salt thereof |
TWI411607B (zh) | 2005-11-14 | 2013-10-11 | Vitae Pharmaceuticals Inc | 天門冬胺酸蛋白酶抑制劑 |
US7872028B2 (en) | 2006-04-05 | 2011-01-18 | Vitae Pharmaceuticals, Inc. | Diaminopropanol renin inhibitors |
WO2008036216A1 (en) | 2006-09-18 | 2008-03-27 | Vitae Pharmaceuticals, Inc. | Piperidine derivatives as renin inhibitors |
CL2007002689A1 (es) | 2006-09-18 | 2008-04-18 | Vitae Pharmaceuticals Inc | Compuestos derivados de piperidin-1-carboxamida, inhibidores de la renina; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hipertension, insuficiencia cardiaca, fibrosis cardiaca, entre otras. |
WO2009096996A1 (en) | 2007-06-20 | 2009-08-06 | Smithkline Beecham Corporation | Renin inhibitors |
EP2170815A2 (en) | 2007-06-20 | 2010-04-07 | Vitae Pharmaceuticals, Inc. | Renin inhibitors |
US7773441B2 (en) * | 2008-06-18 | 2010-08-10 | Micron Technology, Inc. | Memory malfunction prediction system and method |
US20110160300A1 (en) | 2008-06-20 | 2011-06-30 | Marlys Hammond | Renin Inhibitors and Methods of Use Thereof |
MX2010014557A (es) | 2008-06-26 | 2011-02-15 | Vitae Pharmaceuticals Inc | Sales de 2-((r)-(3-clorofenil)((r)-1-((s)-2-(metilamino)-3-((r)-te trahidro-2h-piran-3-il)propilcarbamoil)piperidin-3-il)metoxi)etil carbamato de metilo. |
AR077692A1 (es) | 2009-08-06 | 2011-09-14 | Vitae Pharmaceuticals Inc | Sales de 2-((r)-(3-clorofenil) ((r)-1-((s) -2-(metilamino)-3-((r)-tetrahidro-2h-piran-3-il) propilcarbamoil) piperidin -3-il) metoxi) etilcarbamato de metilo |
-
2007
- 2007-09-14 CL CL200702689A patent/CL2007002689A1/es unknown
- 2007-09-17 TW TW096134810A patent/TWI403510B/zh not_active IP Right Cessation
- 2007-09-17 PE PE2007001252A patent/PE20080843A1/es not_active Application Discontinuation
- 2007-09-17 AR ARP070104098A patent/AR062797A1/es unknown
- 2007-09-18 AU AU2007297729A patent/AU2007297729C1/en not_active Ceased
- 2007-09-18 RS RS20130064A patent/RS52679B/sr unknown
- 2007-09-18 DK DK07838381.7T patent/DK2074108T3/da active
- 2007-09-18 SI SI200731161T patent/SI2074108T1/sl unknown
- 2007-09-18 CA CA002663263A patent/CA2663263A1/en not_active Withdrawn
- 2007-09-18 BR BRPI0718460-3A patent/BRPI0718460A2/pt not_active IP Right Cessation
- 2007-09-18 PT PT78383817T patent/PT2074108E/pt unknown
- 2007-09-18 MX MX2009002740A patent/MX2009002740A/es active IP Right Grant
- 2007-09-18 PL PL07838381T patent/PL2074108T6/pl unknown
- 2007-09-18 EP EP07838381.7A patent/EP2074108B3/en active Active
- 2007-09-18 WO PCT/US2007/020164 patent/WO2008036247A1/en active Application Filing
- 2007-09-18 US US12/311,012 patent/US8198453B2/en not_active Expired - Fee Related
- 2007-09-18 JP JP2009528331A patent/JP5331695B2/ja not_active Expired - Fee Related
- 2007-09-18 ES ES07838381T patent/ES2400009T7/es active Active
- 2007-09-18 EP EP11186691.9A patent/EP2581366A1/en not_active Withdrawn
- 2007-09-18 CN CN2007800391198A patent/CN101528723B/zh not_active Expired - Fee Related
- 2007-09-18 KR KR1020097007791A patent/KR20090064582A/ko not_active Application Discontinuation
- 2007-09-18 NZ NZ575803A patent/NZ575803A/en not_active IP Right Cessation
-
2009
- 2009-10-05 HK HK09109173.1A patent/HK1129115A1/xx not_active IP Right Cessation
-
2012
- 2012-05-11 US US13/469,562 patent/US8580823B2/en not_active Expired - Fee Related
-
2013
- 2013-02-20 HR HRP20130144TT patent/HRP20130144T4/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20130144T1 (en) | Renin inhibitors | |
HK1176601A1 (zh) | 抑制劑 | |
GB0619753D0 (en) | Enzyme inhibitors | |
EP2229363A4 (en) | Renin Inhibitors | |
IL194339A0 (en) | Enzyme inhibitors | |
AP2009004784A0 (en) | Matrix metallproteinase inhibitors | |
IL186038A0 (en) | Polymeric inhibitors for enhanced planarization | |
IL193150A0 (en) | Secondary amines as renin inhibitors | |
EP2023727A4 (en) | PROSTAGLANDINTRANSPORTER INHIBITORS | |
EP1910272A4 (en) | INHIBITORS OF THE RENINE | |
ZA200808419B (en) | Primary amines as renin inhibitors | |
EP2064177A4 (en) | PROTEASE INHIBITORS | |
GB0624187D0 (en) | HDAC inhibitors | |
IL173706A0 (en) | Corrosion inhibitors | |
GB0608844D0 (en) | Enzyme inhibitors | |
EP2177529A4 (en) | NEW DE-SECRETASE INHIBITOR | |
GB0617161D0 (en) | Enzyme inhibitors | |
EP2222662A4 (en) | INHIBITORS OF KYNURENINE AMINO TRANSFERASE | |
EP2190811A4 (en) | INHIBITORS OF THE RENIN | |
EP2188256A4 (en) | INHIBITORS OF THE RENIN | |
EP2076490A4 (en) | INHIBITORS OF CATHEPSIN B | |
GB0714941D0 (en) | Inhibitors | |
GB0622367D0 (en) | Phosphodiesterase inhibitors | |
GB0713152D0 (en) | Phosphodlesterase inhibitors | |
GB0720364D0 (en) | Inhibitor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20160918 |